论文部分内容阅读
目的:探讨糖脉康颗粒联合胰岛素强化治疗2型糖尿病(type 2 diabetes mellitus,T2DM)的临床观察及对患者血脂和内皮素-1(ET-1)的影响。方法:将滨州市人民医院收治的124例T2DM患者采用随机数字表法分为对照组和观察组各62例。在常规治疗基础下,对照组给予胰岛素强化治疗,观察组在对照组治疗的基础上联合应用糖脉康颗粒治疗。比较两组患者临床疗效、血糖相关指标、血脂和血清ET-1水平及低血糖事件的发生率。结果:治疗后,观察组显效率为83.9%,显著高于对照组的67.7%(P<0.05)。与对照组相比,观察组空腹血糖(fasting plasma glucose,FPG)(7.2±0.4)VS(7.9±0.5)mmol·L~(-1),餐后2 h血糖(2 h plasma glucose,2 h PG)(8.5±0.5)VS(9.4±0.6)mmol·L~(-1),糖化血红蛋白A1c(glycosylated hemoglobin A1c,Hb A1c)(7.0%±0.4%)VS(7.6%±0.5%)水平显著降低,血脂总胆固醇(total cholesterol,TC)(4.36±0.82)VS(5.21±0.94)mmol·L~(-1),甘油三酯(triglyceride,TG)(1.93±0.68)VS(2.20±0.53)mmol·L~(-1),低密度脂蛋白胆固醇(low density lipoprotein cholesterol,LDL-C)(3.10±0.54)VS(3.90±0.64)mmol·L~(-1)水平显著降低,高密度脂蛋白胆固醇(high density lipoprotein cholesterol,HDL-C)(1.59±0.35)VS(1.29±0.32)mmol·L~(-1)水平显著升高,ET-1(70.2±7.4)VS(75.6±8.3)ng·L~(-1)水平显著降低,比较都有统计学差异(P<0.05)。治疗过程中,低血糖发生率为8.1%,与对照组4.8%的发生率比较差异不显著。结论:糖脉康颗粒联合胰岛素强化治疗T2DM的临床效果可靠,能够显著提高疗效,改善血糖、血脂指标,降低ET-1水平,且不会增加低血糖等不良反应发生率,临床上值得推广使用。
Objective: To investigate the clinical observation of type 2 diabetes mellitus (T2DM) and its effect on serum lipids and endothelin-1 (ET-1) in rats treated with Tangmaikang granule combined with insulin. Methods: One hundred and twenty-two patients with T2DM admitted to Binzhou People’s Hospital were divided into control group and observation group by random number table. In the conventional treatment based on the control group given insulin intensive treatment, the observation group in the control group based on the combination of Tangmaikang particles treatment. The clinical efficacy, blood glucose related indicators, serum lipids and serum ET-1 levels and the incidence of hypoglycaemic events were compared between the two groups. Results: After treatment, the markedly effective rate in the observation group was 83.9%, significantly higher than that in the control group (67.7%, P <0.05). Compared with the control group, fasting plasma glucose (FPG) (7.2 ± 0.4) VS (7.9 ± 0.5) mmol·L -1, 2 h plasma glucose (2 h (8.5 ± 0.5) VS (9.4 ± 0.6) mmol·L -1, Hb A1c (7.0% ± 0.4%) vs 7.6% ± 0.5% (4.36 ± 0.82) VS (5.21 ± 0.94) mmol·L -1, triglyceride (TG) (1.93 ± 0.68) VS (2.20 ± 0.53), decreased total cholesterol (TC) mmol·L -1, LDL-C 3.10 ± 0.54 VS 3.90 ± 0.64 mmol·L -1, and the levels of high-density lipids The level of HDL-C (1.59 ± 0.35) VS (1.29 ± 0.32) mmol·L -1 was significantly higher in ET-1 (70.2 ± 7.4) VS (75.6 ± 8.3) ng · L ~ (-1) levels were significantly lower than the control group (all P <0.05). During the course of treatment, the incidence of hypoglycemia was 8.1%, which was not significantly different from that of the control group (4.8%). CONCLUSION: Tangmaikang granule combined with insulin fortified treatment of T2DM has reliable clinical effect, which can significantly improve the curative effect, improve blood glucose and blood lipid, reduce the level of ET-1, and will not increase the incidence of adverse reactions such as hypoglycemia. It is worth to be used clinically .